On February 26, Dr. Chen Yongqi, Chairman and Chief Scientist of Resproly, participated in the high-level talent exchange meeting in Hengqin New Area. Starting from the recent Israeli new crown 'special medicine', which has attracted much attention, he shared the research and development and industrial experience of inhaled preparations. And conducted in-depth exchanges with high-level talents, experts and scholars from Zhuhai and Macao.
Dr. Chen Yongqi shared on the spot
On February 16, the Israeli Embassy in China issued a message stating that Israeli scientists have discovered a miraculous drug that can cure the new coronary pneumonia, with a cure rate of over 95%. At the beginning of the news report, Dr. Chen verified the content by consulting relevant information. The 'special drug' EXO-CD24 is an innovative compound based on CD-24 exosomes. The exogenous CD-24 protein is packaged in the exosomes and is directly delivered to the patient's lungs by nasal inhalation to eliminate the new coronavirus The fatal 'cytokine storm' caused. The drug is suitable for patients with moderate to severe COVID-19. However, the current study has only completed the Phase I clinical trial, and more powerful clinical data support should be provided.
When it comes to exosome inhalation, Dr. Chen introduced the research progress of related content. One of the articles published in the journal Nature-Communication showed that the delivery of lung stem cell secretions through aerosol inhalation can repair the cause of mice and rats. Lung injury caused by pulmonary fibrosis; a report in Cells magazine believes that the treatment of COVID-19 through aerosolized MSCs-Exo can solve the problem of intravenous administration of MSCs that may lead to the accumulation or agglomeration of the injured microcirculation, reducing mutagenicity and Risk of carcinogenicity.
Dr. Chen said that inhaled administration has great prospects. The drug reaches the lungs (locally targeted), no transient metabolism by the liver, rapid onset of action, high drug utilization, lower treatment doses, reduced system exposure, and less toxic and side effects. It is the most commonly used treatment for asthma/COPD Mode of administration. It is also an ideal way of administration for various lung diseases and neurological diseases. However, Dr. Chen also admitted that the barriers to inhalation drug delivery are very high, involving complex prescription processes, device development, particle engineering technology, clinical trials, etc., and only a few multinational giants are the main players in the world.
'A typical case is that Novartis of Switzerland spent US$440 million to imitate seretide powder for the treatment of asthma, but it still failed in the United States and finally announced its abandonment.'
Finally, Dr. Chen gave a detailed introduction to the development history of inhalation administration, the types of inhalation administration and their respective advantages and disadvantages, the development of inhalation administration formulation technology, and the status of marketed products. At the exchange meeting, Dr. Chen Yongqi conducted in-depth discussions with field colleagues and scholars on R&D, clinical, and industrialization barriers in the development of inhaled preparations.